Wait, we have a special
offer for you!
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Only Available By Prescription
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Tracleer (Bosentan) is an oral medication specifically designed to manage pulmonary arterial hypertension (PAH), a condition characterized by high blood pressure in the arteries that supply blood to the lungs. As a dual endothelin receptor antagonist, Bosentan effectively blocks the action of endothelin, a natural substance that constricts blood vessels and elevates blood pressure in the lungs. By widening these vessels, Tracleer helps to improve symptoms such as shortness of breath and enhances overall physical activity tolerance. Approved by various health authorities worldwide, including the FDA, Tracleer is a cornerstone therapy for patients diagnosed with PAH.
Before you buy Tracleer, it is crucial that you talk to your healthcare provider about potential side effects and Tracleer price.
| Fact Table | |
|---|---|
| Formula | C27H29N5O6S |
| License | FDA approved |
| Bioavailability | ~50% |
| Legal status | Prescription Drugs |
| Chemical Name | Bosentan |
| Elimination half-life | ~5 hours |
| Dosage (Strength) | 62.5 mg and 125 mg tablets |
| Pregnancy | Contraindicated; teratogenic effects |
| Brands | Tracleer |
| Protein binding | ~98% |
| PubChem CID | 104865 (Bosentan) |
| MedlinePlus | a603017 |
| ChEBI | 51305 (Bosentan) |
| ATC code | C02KX01 |
| DrugBank | DB00559 (Bosentan) |
| KEGG | D01978 (Bosentan) |
| Routes of administration | Oral |
Bosentan Tracleer should be taken strictly as prescribed by a healthcare professional. The usual starting dose is 62.5 mg, taken orally twice daily (morning and evening), with or without food. After 4 weeks, the dosage typically increases to 125 mg twice daily, depending on the patient's liver function and overall response to the initial treatment.
Active Ingredient: Bosentan.
Tracleer can cause serious liver injury. Liver function tests should be performed monthly, and doses adjusted, or therapy interrupted as necessary.
Tracleer is classified under pregnancy category X and can cause harm to an unborn baby. It is essential that women of childbearing age use reliable contraception during treatment and undergo monthly pregnancy tests.
Treatment with Tracleer may result in a decrease in hemoglobin and hematocrit levels. Regular blood tests are recommended to monitor these levels.
Tracleer has the potential to interact with other medications, which can alter its effectiveness and increase the risk of adverse effects. Notable interactions include Cyclosporine A, Glyburide, Antiretrovirals, Anticoagulants and Hormonal Contraceptives.
While Tracleer is effective in treating PAH, it can cause side effects, some of which may require medical attention. Common side effects include:
What is the use of Tracleer?
Tracleer (bosentan) is used to treat pulmonary arterial hypertension (PAH), a condition characterized by high blood pressure in the arteries of the lungs. It helps improve exercise ability and delay the worsening of symptoms in PAH patients.
What class of drug is Tracleer?
Tracleer belongs to a class of drugs known as endothelin receptor antagonists (ERAs). These drugs block the effects of endothelin-1, a substance that causes blood vessels to constrict and increase blood pressure.
What are the ingredients in Tracleer?
The active ingredient in Tracleer is bosentan. Inactive ingredients typically include maize starch, pregelatinized starch, sodium starch glycolate, povidone, magnesium stearate, glyceryl behenate, hypromellose, talc, titanium dioxide, and iron oxide.
Is bosentan effective?
Yes, bosentan is effective in treating pulmonary arterial hypertension. Clinical studies have shown that bosentan can improve exercise capacity, hemodynamics, and delay clinical worsening in PAH patients.
How quickly does bosentan work?
Bosentan's effects can start to be seen within weeks of starting the treatment. Improvement in exercise capacity and other clinical symptoms may be observed after about 4-8 weeks of therapy.
What are the adverse events of bosentan?
Common adverse events of bosentan include:
Severe liver damage and teratogenicity are also significant risks.
Does bosentan lower blood pressure?
Yes, bosentan can lower blood pressure, particularly in the pulmonary arteries. It may also have systemic blood pressure-lowering effects, though it is primarily used for its action on the pulmonary circulation.
What receptors does bosentan block?
Bosentan blocks endothelin receptors, specifically endothelin receptor A (ETA) and endothelin receptor B (ETB). These receptors are involved in the constriction of blood vessels and proliferation of vascular smooth muscle cells.
What is the approved indication for bosentan?
Bosentan is approved for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability and decrease the rate of clinical worsening.
What is the contraindication for bosentan?
Bosentan is contraindicated in patients with moderate to severe liver impairment, in pregnant women due to teratogenicity, and in those who are hypersensitive to bosentan or any of its components. It should also not be used in combination with cyclosporine A or glyburide due to potential drug interactions.
